Norepinephrine

Introduction Overview

Generic Name

norepinephrine

Brand Name

Levophed, Levophed Bitartrate

Dosage Form

injectable solution

Drug Class

Catecholamines, Vasopressors

Pharmacokinetics

Absorption:
Norepinephrine is administered parenterally, predominantly by intravenous infusion due to its poor oral bioavailability. The molecule is highly polar and is rapidly inactivated when taken orally; therefore, it is not absorbed via the gastrointestinal tract. Upon intravenous administration, norepinephrine is rapidly distributed, with an almost immediate onset of action, making it essential for acute emergencies such as hypotension and shock. The absorption phase is effectively bypassed by intravenous administration.

Distribution:
After intravenous administration, norepinephrine exhibits a rapid distribution phase characterized by volume of distribution approximating 0.2–0.3 L/kg, reflecting its confinement primarily to plasma and extracellular fluid. Plasma protein binding is low. Due to its hydrophilic nature, the drug does not significantly cross the blood-brain barrier. It rapidly reaches adrenergic receptors in peripheral vascular smooth muscle, causing potent vasoconstriction.

Metabolism:
Norepinephrine is metabolized primarily by the enzymes monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT). These enzymes are distributed in various tissues, including the liver, kidneys, and sympathetic nerve terminals. MAO catalyzes the oxidative deamination of norepinephrine to dihydroxyphenylglycol (DHPG), while COMT methylates catechol groups. The rapid enzymatic metabolism contributes to the drug's very short plasma half-life.

Elimination:
The elimination of norepinephrine occurs primarily via metabolism rather than renal excretion of unchanged drug. Its plasma half-life is approximately 2 to 2.5 minutes, necessitating continuous infusion to maintain therapeutic levels. Metabolites such as vanillylmandelic acid (VMA) are excreted in urine. Renal clearance involves excretion of these metabolites rather than the parent compound. Clinical clearance can be affected by tissue perfusion and enzymatic activity, important considerations during critical illness.

Dosage Forms

Available Dosage Forms:
Norepinephrine is formulated exclusively for parenteral use due to its instability and inactivation via the gastrointestinal tract. The available commercial preparations include various sterile injectable solutions:
- Injectable solution: 4 mg/250 mL Dextrose 5% (D5%)
- Injectable solution: 8 mg/250 mL Dextrose 5% (D5%)
- Injectable solution: 8 mg/250 mL Sodium Chloride 0.9% (NaCl 0.9%)
- Intravenous solution concentrations: 1 mg/mL; 16 mg/250 mL D5%; 16 mg/250 mL NaCl 0.9%; 4 mg/250 mL D5%; 4 mg/250 mL NaCl 0.9%; 8 mg/250 mL D5%; 8 mg/250 mL NaCl 0.9%; 8 mg/50 mL NaCl 0.9%; and 8 mg/500 mL D5%.

Dosages for Adults and Adolescents:
Dosing is individualized, titrated to effect in critical care settings. Norepinephrine is administered as a continuous intravenous infusion, starting often in the range of 0.05 to 0.1 mcg/kg/min and adjusted to maintain adequate blood pressure. Doses typically range from 0.01 mcg/kg/min up to 3 mcg/kg/min; higher doses may be used in refractory shock under close monitoring. Continuous hemodynamic monitoring is mandatory to guide therapy.

Specific Patient Populations:
In patients with impaired hepatic or renal function, there is no specific dosage adjustment recommended due to rapid metabolism and clearance. However, caution is advised since the physiological response may differ. Pediatric dosing is not well established; use in this population requires specialist supervision. Use during pregnancy is reserved for severe hypotension only when benefits outweigh risks. Elderly patients may be more sensitive to vasopressor effects, necessitating careful dose titration.

Mechanism Of Action

Norepinephrine functions as a potent vasopressor primarily through its agonistic effect on alpha-1 adrenergic receptors located on vascular smooth muscle. Binding to these receptors activates Gq protein-coupled receptors, stimulating phospholipase C, which subsequently increases intracellular inositol triphosphate (IP3) and diacylglycerol (DAG). This leads to the release of calcium from sarcoplasmic reticulum stores, resulting in smooth muscle contraction and vasoconstriction that elevates systemic vascular resistance and blood pressure.

Additionally, norepinephrine has modest agonist activity at beta-1 adrenergic receptors in the heart, leading to increased heart rate (positive chronotropic effect) and enhanced myocardial contractility (positive inotropic effect). This is mediated through the stimulation of adenylate cyclase via Gs protein-coupled receptors, increasing cyclic AMP and activating protein kinase A pathways that phosphorylate calcium channels, facilitating calcium influx.

At cellular levels, norepinephrine induces vasoconstriction of arterioles, redistributing blood flow to vital organs such as the heart and brain. It also reduces splanchnic, renal, and cutaneous blood flow, augmenting effective circulating volume and improving perfusion pressure. This mechanism is essential during shock states where hypotension compromises organ perfusion.

Comparatively, norepinephrine differs from epinephrine due to its predominant alpha-adrenergic effects and comparatively weaker beta-2 receptor activation, which limits vasodilation. Clinical studies have demonstrated norepinephrine’s superior profile for managing septic shock because it increases mean arterial pressure with less tachycardia and arrhythmogenic potential compared to dopamine or epinephrine. This efficacy has been validated in large randomized controlled trials and meta-analyses.

Research evidence supports norepinephrine's critical role in advanced cardiac life support protocols and management of distributive shock, emphasizing its rapid onset and short duration of action, which allow fine-tuned hemodynamic control in critically ill patients.

Pharmacological Actions

Potent alpha-1 adrenergic receptor agonist causing strong vasoconstriction.
Beta-1 adrenergic receptor agonist effects resulting in increased heart rate and myocardial contractility.
Increases systemic vascular resistance to elevate blood pressure in hypotensive states.
Redistributes blood flow to vital organs during shock by constricting peripheral vascular beds.
Minimal beta-2 adrenergic receptor activity, limiting vasodilation.
Rapid onset and short duration of action due to rapid metabolism by MAO and COMT.
Enhancement of cardiac output through positive inotropic and chronotropic effects.
Used as a vasopressor agent to restore vascular tone and improve perfusion.
Influences intracellular signaling pathways involving calcium mobilization and cAMP.
Acts primarily on vascular smooth muscle to increase peripheral vascular resistance.
May cause reflex bradycardia secondary to increased blood pressure.
In clinical use during resuscitation for maintaining blood pressure in septic and cardiogenic shock.
Limited central nervous system penetration due to hydrophilic properties.
Can decrease splanchnic, renal, and cutaneous blood flow through vasoconstriction.
Potential to increase myocardial oxygen consumption due to cardiac stimulation.

Therapeutic Or Clinical Uses

Treatment of acute hypotension and shock, including septic, cardiogenic, and neurogenic shock.
Vasopressor support during advanced cardiac life support (ACLS) protocols in cardiac arrest.
Maintenance of blood pressure during surgical procedures with anesthesia-induced hypotension.
Management of patients with severe blood pressure drops due to anesthesia or trauma.
Restoration of vascular tone in distributive shock conditions.
Adjunctive agent for circulatory support in critically ill patients with compromised hemodynamics.
Used in intensive care units for vasopressor therapy to maintain mean arterial pressure above critical thresholds.
Treatment of hypotension refractory to fluid resuscitation.
Supportive therapy after cardiac surgery to maintain systemic vascular resistance.
Management of vasodilatory shock states unresponsive to other vasopressors.
Temporary treatment of hypotension associated with various medical conditions.
Used in emergency medicine and critical care for rapid hemodynamic stabilization.
Adjunct to other vasoactive agents when monotherapy is insufficient.
Off-label uses include maintaining blood pressure in some overdose scenarios.
Preferred vasopressor in septic shock per current clinical guidelines.

Side Or Adverse Effects

Extravasation may cause local tissue necrosis and skin irritation around the injection site.
Severe headache related to elevated blood pressure.
Bradycardia due to reflex vagal response from increased systemic vascular resistance.
Arrhythmias resulting from beta-1 adrenergic stimulation.
Hypertension from excessive vasoconstriction.
Ischemic complications including limb ischemia due to vasoconstriction.
Signs of allergic reactions such as hives, swelling, or difficulty breathing.
Visual disturbances including blurred vision due to hypertensive effects.
Chest pain and possible angina from increased myocardial oxygen demand.
Sweating and pallor associated with sympathetic stimulation.
Nausea and vomiting from autonomic responses.
Dyspnea or respiratory distress caused by vascular changes.
Sudden numbness, weakness, or cold sensation in extremities.
Reduced urine output indicative of renal hypoperfusion.
Mottling or cyanosis of lips and extremities signaling poor peripheral perfusion.

Precautions

Monitor injection sites closely to prevent and detect extravasation-induced tissue injury.
Use with caution in patients with known coronary artery disease due to increased myocardial oxygen consumption.
Cautiously administer during pregnancy; only use if benefits outweigh risks to fetus.
Evaluate renal function, as renal perfusion may be compromised depending on dose and duration.
Avoid abrupt withdrawal to prevent rebound hypotension.
Careful hemodynamic monitoring required to titrate dose and avoid excessive hypertension.
Precaution in patients with hyperthyroidism to avoid exaggerated pressor response.
Monitor for signs of peripheral ischemia, especially in elderly or peripheral vascular disease patients.
Avoid use in hypovolemia until adequate fluid resuscitation is achieved.
Use sparingly in patients with pheochromocytoma or other catecholamine-secreting tumors.
Consider potential drug interactions, especially with MAO inhibitors and other sympathomimetic agents.
Careful use in patients with arrhythmias or conduction abnormalities.
Monitor blood glucose levels, as catecholamines can induce hyperglycemia.
Ensure adequate airway and respiratory support due to risk of bronchospasm in asthmatic patients.
Caution in patients with pre-existing hypertension or during pregnancy/lactation.

Warnings

Risk of severe ischemia and necrosis if medication extravasates into surrounding tissue.
Potential for serious cardiac arrhythmias including ventricular tachycardia and fibrillation.
May cause hypertensive crisis and severe headache secondary to excessive vasoconstriction.
May induce reflex bradycardia; monitor heart rate carefully during administration.
Requires continuous hemodynamic monitoring given short half-life and potent effects.
Use only by experienced healthcare providers in intensive care or emergency settings.
Sudden numbness, weakness, or cold feeling may indicate occlusive vascular complications.
Can cause reduced urine output signaling renal hypoperfusion or failure.
Blue discoloration of lips, fingernails or skin (mottled skin) warrants immediate evaluation.
Severe headache, vision changes, or neurological symptoms necessitate urgent medical assessment.
Avoid extravasation by ensuring proper intravenous access and monitoring.
Concomitant use with monoamine oxidase inhibitors can cause hypertensive crisis.
Should be discontinued gradually under monitoring to avoid rebound hypotension.
Not intended for bolus injection due to risk of cardiac complications.
Pregnant and breastfeeding women require careful risk-benefit assessment before administration.

Contraindication

Known hypersensitivity to norepinephrine or any components of the formulation.
Use in patients with mesenteric or peripheral vascular thrombosis due to risk of worsening ischemia.
Absolute contraindication for subcutaneous, intramuscular, or accidental extravascular injection.
Concomitant use with non-selective MAO inhibitors without appropriate washout period.
Not to be used to treat hypovolemia before adequate volume resuscitation.
Patients with uncorrected severe anemia may be at risk due to vasoconstriction.
Severe peripheral arterial disease predisposing to critical limb ischemia.
Extreme caution or avoidance in patients with uncontrolled hypertension.
Patients with ventricular fibrillation as norepinephrine can exacerbate arrhythmias.
Avoid use if vascular access is unreliable or extravasation risk is high.
Contraindicated in patients with sulfite sensitivity due to preservatives in some formulations.
Not indicated for chronic hypotension; used only for acute emergency management.
Avoid use in patients with closed-angle glaucoma due to potential increase in intraocular pressure.
Contraindicated where dopamine or other vasopressors provide safer alternatives.
Not recommended for use without close hemodynamic monitoring.

Drug Interactions

Monoamine oxidase (MAO) inhibitors (e.g., isocarboxazid, phenelzine) potentiate norepinephrine effects, increasing risk of hypertensive crisis.
Tricyclic antidepressants can enhance vasopressor effects through inhibition of norepinephrine reuptake.
Beta blockers may attenuate cardiac beta-1 receptor effects but leave alpha vasoconstriction unopposed, risking hypertension.
Sympathomimetic drugs can have additive or synergistic effects, increasing risk of excessive vasoconstriction and hypertension.
Anesthetics may potentiate or blunt cardiovascular responses to norepinephrine.
Drugs that reduce adrenergic receptor sensitivity or number may inhibit norepinephrine efficacy.
Lithium may reduce norepinephrine release and action, diminishing efficacy.
Amphetamines and cocaine may enhance sympathomimetic effects leading to adverse cardiovascular events.
Vasodilators may counteract norepinephrine’s effects, requiring dose adjustments.
Tricyclic antidepressants can enhance hypertensive effects and arrhythmogenic potential.
Antihypertensive agents may interact unpredictably, necessitating careful monitoring.
Sympatholytics such as alpha-blockers may antagonize norepinephrine’s vasoconstrictive action.
MAO inhibitors combined with norepinephrine can cause severe hypertension and hypertensive crises.
Methyldopa and reserpine may affect endogenous norepinephrine stores and drug responses.
Interaction with herbal supplements like St. John’s Wort could affect norepinephrine metabolism and effect.

Preparations Of The Drug

Levophed injection concentrate for intravenous infusion.
Sterile solutions for intravenous administration with strengths including 1 mg/mL and diluted bags ranging from 4 mg/250 mL to 16 mg/250 mL.
Solutions prepared in 5% Dextrose (D5%) or 0.9% Sodium Chloride (NaCl) to optimize stability and compatibility.
Single-use vials or pre-mixed infusion bags designed for critical care settings.
May contain sulfite preservatives which require allergy consideration.
Commercial preparations available under brand names Levophed and Levophed Bitartrate.
Stored protected from light due to catecholamine sensitivity to degradation.
Dilution and preparation require aseptic technique and designated infusion pumps.
Formulations suitable only for parenteral administration; no oral or topical forms available.
Available in various bag sizes to allow tailored dosing in continuous infusion.
Some preparations contain buffering agents to maintain pH and enhance stability.
Established shelf-life recommendations when refrigerated and once opened.
Used under strict hospital pharmacy controls to ensure potency and sterility.
Packaging includes safety labeling on vasopressor risk and extravasation potential.
Preparation guidelines emphasize minimizing exposure to light and air to prevent oxidation.